Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Moringa oleifera has attracted scientific interest for its potential anticancer properties, including possible effects against leukemia. Laboratory (in vitro) studies have shown that extracts from moringa leaves, seeds, and bark can induce apoptosis (programmed cell death) and inhibit the proliferation of various cancer cell lines, including human acute myeloid leukemia cells. For example, a study published in Food and Chemical Toxicology (2011) demonstrated that moringa leaf extract exhibited cytotoxic activity against HL-60 leukemia cells, leading to reduced cell viability and increased apoptotic markers.

The proposed mechanisms behind these effects include the presence of bioactive compounds such as isothiocyanates, niazimicin, and quercetin, which can modulate oxidative stress, alter cell cycle progression, and promote apoptosis in cancerous cells. Additionally, moringa’s antioxidant and anti-inflammatory properties may contribute to its potential anticancer effects.

However, it is crucial to note that most of the evidence comes from preclinical studies (cell cultures and animal models). There is a lack of robust human clinical trials evaluating the efficacy or safety of moringa for leukemia patients. While the in vitro results are promising, translating these findings to clinical practice requires more research. As such, moringa should not be considered a substitute for conventional leukemia treatments, but rather a subject of ongoing investigation for its adjunctive potential.

More about moringa
More about Leukemia

Other ingredients used for Leukemia

Other health conditions supported by moringa

Products containing moringa